Quality of life after islet transplantation: data from the GRAGIL 1 and 2 trials

Diabet Med. 2009 Jun;26(6):617-21. doi: 10.1111/j.1464-5491.2009.02731.x.


Background: Rigorous assessment of health-related quality of life (HRQL) is mandatory to establish the benefits of islet transplantation.

Methods: The 36-Item Short Form Health Survey (SF-36) and the Diabetes Quality of Life (DQOL) scales were completed by patients included in an Islet Transplantation Alone (ITA) trial (n = 10) and an Islet After Kidney (IAK) trial (n = 10).

Results: The two populations differed by HRQL scores at baseline, with poorer scores in ITA patients. SF-36 scores for physical limitations, bodily pain, general health perception, social functioning, and health transition improved significantly in ITA patients 6 and 12 months post transplantation. The DQOL global score was significantly improved at 6 months and remained so at 12 months, because of a significant improvement in the dimensions of satisfaction and impact of diabetes. No improvement was observed in the IAK patients.

Conclusion: HRQL assessment may help in the selection of candidates with brittle diabetes for islet transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 1 / surgery*
  • Female
  • Humans
  • Islets of Langerhans Transplantation*
  • Male
  • Middle Aged
  • Quality of Life*
  • Treatment Outcome